Gary J. Kelloff

311 papers receiving 19.9k citations

Gary J. Kelloff's Hit Papers

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia 2017 · 442 citations
4420+8+17Years since publication5001k1.5k2k

Peers

Gary J. Kelloff
Comparison fields: 5 of 158
  • Pharmacology 3.8k
  • Cancer Research 2.6k
  • Biochemistry 1.1k
  • Oncology 2.8k
  • Molecular Medicine 812
Replace Ronald A. Lubet with:
Ronald A. Lubet United States
Vernon E. Steele United States
Chinthalapally V. Rao United States
Bandaru S. Reddy United States
Zigang Dong United States
Andrew J. Dannenberg United States
Anupam Bishayee United States
Fazlul H. Sarkar United States
Frank Louis Meyskens United States
Kwang Seok Ahn South Korea
Gary J. Kelloff relative to Ronald A. Lubet United States Ronald A. Lubet's profile →
Citations per field
00.5×2×2.5×
Ronald A. Lubet · 1×
Citations per year

Countries citing papers authored by Gary J. Kelloff

Since Specialization
Citations

This map shows the geographic impact of Gary J. Kelloff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary J. Kelloff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary J. Kelloff more than expected).

Fields of papers citing papers by Gary J. Kelloff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary J. Kelloff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary J. Kelloff. The network helps show where Gary J. Kelloff may publish in the future.

Co-authors

The 25 scholars most cited alongside Gary J. Kelloff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gary J. Kelloff Line = papers co-authored together Gary J. Kelloff links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 316 papers — load more, or switch the sort, to bring in the rest.

#Work
1
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Hit paper breakdown →
20002135
2
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Hit paper breakdown →
2005558
3
Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer.
1999531
4 2008450
5
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia
Hit paper breakdown →
2017442
6
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
2000435
7
Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
2000400
8 2000394
9 1999365
10
Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review.
1990358
11
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
2002316
12 2012287
13 1999283
14
Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam.
1996275
15
Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion.
1997268
16 2000240
17
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
2000235
18 2000232
19
Screening of potential chemopreventive agents using biochemical markers of carcinogenesis.
1994230
20 2006228

About Gary J. Kelloff

Gary J. Kelloff is a scholar working on Cancer Research, Pharmacology, Oncology, Immunology and Molecular Biology, having authored 316 papers that have together received 21.5k indexed citations. Recurring topics across this work include Carcinogens and Genotoxicity Assessment (67 papers), Inflammatory mediators and NSAID effects (59 papers), T-cell and Retrovirus Studies (39 papers), Cancer and biochemical research (33 papers), Science, Research, and Medicine (22 papers), Bioactive Compounds and Antitumor Agents (16 papers), Estrogen and related hormone effects (16 papers) and Prostate Cancer Treatment and Research (15 papers). The work is most often cited by research in Pharmacology (3.8k citations), Cancer Research (2.6k citations), Biochemistry (1.1k citations), Oncology (2.8k citations) and Molecular Medicine (812 citations). Gary J. Kelloff has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Vernon E. Steele, Ronald A. Lubet, Caroline C. Sigman, Charles W. Boone, Chinthalapally V. Rao, James A. Crowell, Karen Seibert, Ernest T. Hawk, Ron Lubet and Bandaru S. Reddy. Their work appears in journals such as Journal of Cellular Biochemistry, Carcinogenesis, Clinical Cancer Research, JNCI Journal of the National Cancer Institute and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact